Crescent Biopharma, Inc. (CBIO) vs MiMedx Group, Inc (MDXG)

Crescent Biopharma, Inc. and MiMedx Group, Inc are both Biotechnology companies. Crescent Biopharma, Inc. and MiMedx Group, Inc are of similar size ($480.6M and $478.6M). MiMedx Group, Inc grew revenue faster over the last twelve months: −22.8% against −45.1%. Crescent Biopharma, Inc. has the higher net margin (0.00% vs −6.32%) and the higher return on invested capital (0.00% vs −17.4%). Across the 17 metrics below, MiMedx Group, Inc leads on 11 and Crescent Biopharma, Inc. on 6.

Valuation

Metric CBIO MDXG Biotechnology median
P/E n/m n/m 10.60
P/S 337.85 1.59 9.40
P/B 2.58 2.29 2.13
Price to free cash flow n/m 25.38 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales 227.76 1.25 9.02
Earnings yield (49.85%) (3.91%) (32.88%)
Free cash flow yield (17.46%) 3.94% (23.13%)

Profitability

Metric CBIO MDXG Biotechnology median
Gross margin 19.72% 77.29% 68.51%
Operating margin 0.00% (8.28%) 0.00%
Net margin 0.00% (6.32%) 0.00%
Free cash flow margin 0.00% 6.26% 0.00%
Return on equity (101.95%) (8.53%) (51.96%)
Return on assets (88.26%) (6.58%) (46.06%)
Return on invested capital 0.00% (17.40%) 0.00%

Growth

Metric CBIO MDXG Biotechnology median
Revenue growth (TTM) (45.09%) (22.80%) 6.76%
EPS growth (last fiscal year) 78.20% 14.29% 29.88%
Revenue growth, 5-year CAGR 257.77% 11.02% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CBIO MDXG Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 9.66 4.35 4.97
Net debt to EBITDA 1.40 (1.88) 1.01

Dividend

Metric CBIO MDXG Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric CBIO MDXG Biotechnology median
Market cap 480.64m 478.63m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack